Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
F B Waldo, … , L Beischel, C D West
F B Waldo, … , L Beischel, C D West
Published June 1, 1985
Citation Information: J Clin Invest. 1985;75(6):1786-1795. https://doi.org/10.1172/JCI111891.
View: Text | PDF
Research Article

A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

  • Text
  • PDF
Abstract

C3 nephritic factor (C3NeF) was used to assess the formation of the fluid-phase amplification convertase, C3b,Bb, in 37 serum specimens from 24 patients with systemic lupus erythematosus (SLE). C3b,Bb formation was measured by the concentration of Ba, released when C3b,B is activated. Incubation of normal human serum (NHS) with C3NeF accelerates C3b amplification loop turnover with the formation of large quantities of C3b,Bb. In contrast, sera from 22 of 24 patients with SLE formed little or no convertase when incubated with C3NeF. C3 conversion to C3b was commensurately reduced. The inhibition could not be attributed to depressed serum concentrations of C3, factor B, or classical pathway components. Inhibitor present in excess could be demonstrated in 23 of 34 specimens of SLE serum by mixing experiments. The spontaneous convertase formation that occurs when a portion of the serum H is inactivated with F(ab')2 anti-H was also shown to be inhibited in SLE serum. The inhibition was found, however, to be H dependent in that convertase formation was normal in SLE serum depleted of H. It is concluded that the C3b in most SLE sera is unusually susceptible to inactivation by H, but a functional abnormality was not demonstrable in either C3 or H isolated from SLE serum. The inhibition could be simulated in NHS by addition of heparin, 100 micrograms/ml. In vivo, inhibition of convertase formation could interfere with the solubilization and disposal of immune complexes by reducing the deposition of C3b on the immune complex lattice.

Authors

F B Waldo, J Forristal, L Beischel, C D West

×

Total citations by year

Year: 2019 2016 2015 2008 1998 1993 1992 1991 1989 1988 1987 1986 1981 Total
Citations: 1 1 2 1 1 1 1 3 1 1 2 1 1 17
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (17)

Title and authors Publication Year
Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations
F Corvillo, M Okrój, P Nozal, M Melgosa, P Sánchez-Corral, M López-Trascasa
Frontiers in immunology 2019
C3 Glomerulopathy
M Riedl, P Thorner, C Licht
Pediatric Nephrology 2016
„State-of-the-art“: C3-Glomerulopathie und membranoproliferative Glomerulonephritis: Ein Konsensus
B Hohenstein, C Licht, M Wiesener, K Amann, F Schaefer, C Serka, C Bergmann, M Kirschfink, P Zipfel, C Hugo
Der Nephrologe 2015
Pediatric Nephrology
ED Avner, WE Harmon, P Niaudet, N Yoshikawa, F Emma, S Goldstein
Pediatric Nephrology 2015
A hemolytic method for the measurement of nephritic factor
CD West
Journal of Immunological Methods 2008
The Human Complement System in Health and Disease
J Ahearn, A Rosengard
The Human Complement System in Health and Disease 1998
Complement in Health and Disease
K Whaley, M Loos, JM Weiler
1993
Review: Complement and Lupus: Old Concepts and New Directions
JM Porcel, D Vergani
Lupus 1992
Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE)
N Madi, G Steiger, J Estreicher, JA Schifferli
Clinical & Experimental Immunology 1991
Relative Value of Serum C3 and C4 Levels in Predicting Relapse in Systemic Lupus Erythematosus
CD West
American Journal of Kidney Diseases 1991
Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE).
Madi N, Steiger G, Estreicher J, Schifferli JA
Clinical & Experimental Immunology 1991
A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III
CW Clardy, F Judith, CF Strife, CD West
Clinical Immunology and Immunopathology 1989
Lack of complement activation by human IgA immune complexes
H Imai, A Chen, RJ Wyatt, A Rifai
Clinical & Experimental Immunology 1988
A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1)
YC Ng, DK Peters, SA Cederholm-Williams, MJ Walport
Clinical & Experimental Immunology 1987
Quantiation of (C1INH)2 C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation
FB Waldo, CD West
Clinical Immunology and Immunopathology 1987
Complement in the Pathophysiology and Diagnosis of Human Diseases
AP Dalmasso
Critical Reviews in Clinical Laboratory Sciences 1986
Contemporary Nephrology
S Klahr, SG Massry
1981

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts